CAPRALOGICS INC

Capralogics Inc. specializes in advanced biomedical research services, with a focus on immunological testing and virological assay development for novel therapeutic applications. Their core capabilities center on the design and execution of preclinical immunization studies, particularly involving recombinant protein trimer constructs and nanobody discovery platforms targeting conserved viral epitopes such as the CD4 binding site of HIV-1 Env. The firm demonstrates technical proficiency in structural immunology, antigen formulation, and high-specificity serological analysis, enabling the development of broadly neutralizing agents for next-generation vaccine candidates. Their work reflects deep expertise in animal model immunization protocols, monoclonal antibody isolation, and epitope mapping—skills critical to advancing biodefense and infectious disease therapeutics. Capralogics has delivered research services to the Department of Health and Human Services, primarily supporting high-complexity, mission-critical immunology initiatives within public health and biomedical research divisions. Their engagement reflects a focused partnership in translational science, where government-funded objectives require precise laboratory execution and rigorous data integrity standards. The company operates under NAICS 541380, which encompasses specialized testing laboratories conducting biological and immunological analyses for research and development. This positions Capralogics within the niche segment of infectious disease research support, serving federal biodefense and vaccine development programs requiring specialized virology and immunology testing infrastructure. Capralogics Inc. is a small business structured as a 2L entity, headquartered in Gilbertsville, Massachusetts. While currently holding no formal government certifications, its operational focus on high-sensitivity biomedical testing and its alignment with HHS research priorities establish a clear niche in the federal life sciences contracting landscape. The company’s geographic presence supports proximity to regional research institutions and federal biodefense hubs, enhancing its capacity for responsive, collaborative science.